Raloxifene for the treatment and prevention of breast cancer?

Abstract:

:Raloxifene is a member of a family of drugs known as selective estrogen receptor modulators (SERMs). Raloxifene is currently approved by the FDA for the prevention and treatment of osteoporosis in postmenopausal women. SERMs hold the potential to treat and prevent breast cancer, osteoporosis and coronary heart disease. Ongoing clinical trials are in place to address the role of raloxifene and SERMs in each of these areas. We review the pharmacology, clinical utility, safety and tolerability of raloxifene and speculate on what the future holds for SERMs and their use in breast cancer.

authors

Pappas SG,Jordan VC

doi

10.1586/14737140.1.3.334

keywords:

subject

Has Abstract

pub_date

2001-10-01 00:00:00

pages

334-40

issue

3

eissn

1473-7140

issn

1744-8328

pii

ERA010304

journal_volume

1

pub_type

杂志文章
  • Colon and rectal cancer after renal transplantation.

    abstract::Increased cancer risk after renal transplantation is believed to be a consequence of continuous immunosuppression. However, the risk of colorectal cancer (CRC) after renal transplantation is controversial and has received limited study. Accumulating evidence suggests that colon and rectal cancers have different charac...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.8.1339

    authors: Kan M,Gill JS,Wiseman SM

    更新日期:2008-08-01 00:00:00

  • The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.

    abstract:INTRODUCTION:In the recent years, melanoma patients' outcome and survival improved, mainly because of systemic treatment improvement with targeted therapy and checkpoint blockade. Targeted therapy with BRAF and MEK inhibitors was approved to treat patients with unresectable or metastatic melanoma, harboring BRAF V600 m...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2016.1192469

    authors: Amaral T,Nouri N,Garbe C

    更新日期:2016-07-01 00:00:00

  • Treatment options for advanced pancreatic cancer: a review.

    abstract::Advanced pancreatic adenocarcinoma historically has a poor prognosis and the mortality rate has remained unchanged for over a decade. Common treatment options for patients with advanced pancreatic cancer include chemoradiation and/or chemotherapy. Single-agent gemcitabine has been considered the standard of care since...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.115

    authors: Warsame R,Grothey A

    更新日期:2012-10-01 00:00:00

  • Advances in radiation therapy of head and neck cancer.

    abstract::Head and neck cancer is the fifth most common cancer in the USA. Although there have been major improvements in surgical and radiation techniques, the overall survival has not changed significantly in the last decade. The major changes occurring in recent years have been in the ability to preserve organs and to improv...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.4.633

    authors: Popovtzer A,Eisbruch A

    更新日期:2008-04-01 00:00:00

  • Therapeutic endoscopy and endoscopic ultrasound for gastrointestinal malignancies.

    abstract::Gastrointestinal endoscopy and endoscopic ultrasound not only provide strategies to diagnose and stage malignancy, but also to administer palliative and definitive care. Options for anticancer therapy include endoscopic mucosal resection, photodynamic therapy, thermal therapy, self-expanding metal stents and recently,...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.4.705

    authors: Wong RF,Bhutani MS

    更新日期:2005-08-01 00:00:00

  • Systemic therapy for recurrent endometrial cancer: a review of North American trials.

    abstract::While early-stage endometrial cancer is highly curable after hysterectomy for the majority of patients afflicted with this disease, recurrent and metastatic endometrial cancer continues to pose a significant challenge. The median survival of women with advanced or recurrent uterine cancer on most recent clinical trial...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.54

    authors: Dellinger TH,Monk BJ

    更新日期:2009-07-01 00:00:00

  • The role of stereotactic body radiotherapy and stereotactic radiosurgery in the re-irradiation of metastatic spinal tumors.

    abstract::Stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS) are advanced radiotherapy delivery techniques that allow for the delivery of high-dose per fraction radiation. Advances in imaging technology and intensity modulation have allowed SRS and SBRT to be used for the treatment of tumors in close prox...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.940326

    authors: Jain AK,Yamada YJ

    更新日期:2014-10-01 00:00:00

  • Benefits of laparoscopic prostate-sparing radical cystectomy.

    abstract:PURPOSE:Prostate-sparing radical cystectomy has been described in the literature and has proven to be a promising procedure owing to the continence and erectile function results without necessarily compromising the oncologic outcome in selected patients. TECHNIQUE POINTS:A transperitoneal approach is used. Lymph node ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.1.21

    authors: Rozet F,Harmon J,Arroyo C,Cathelineau X,Barret E,Vallancien G

    更新日期:2006-01-01 00:00:00

  • Temozolomide: a novel oral alkylating agent.

    abstract::Temozolomide is an imidazotetrazine with a mechanism of action and efficacy similar to dacarbazine (DTIC). However, it differs from DTIC in that it can be taken orally, degrades spontaneously to an active metabolite and penetrates the blood-brain barrier. It is well tolerated, making it a suitable candidate for combin...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.1.1.13

    authors: Danson SJ,Middleton MR

    更新日期:2001-06-01 00:00:00

  • Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer.

    abstract::Endothelin axis deregulation triggers a series of events that ultimately activate proliferation, invasion, escape from programmed cell death, new vessel formation, abnormal osteogenesis and alteration of nociceptive stimuli. Atrasentan is a novel agent that effectively targets this pathway and is able to inhibit and/o...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.3.419

    authors: Jimeno A,Carducci M

    更新日期:2005-06-01 00:00:00

  • 5th Canadian Melanoma Conference: research frontiers.

    abstract::The prospects for the treatment of metastatic melanoma are improving. Whereas previous scientific meetings dedicated to the treatment of metastatic melanoma patients were overshadowed by our inability to improve overall survival or lengthen the time to progression, the results presented at the most recent meetings are...

    journal_title:Expert review of anticancer therapy

    pub_type:

    doi:10.1586/era.11.62

    authors: van Kempen LC

    更新日期:2011-06-01 00:00:00

  • Controversies over the role of radiation therapy for ductal carcinoma in situ.

    abstract::Ductal carcinoma in situ is a premalignant disease of the breast with a rapidly rising incidence. For women with localized ductal carcinoma in situ, randomized trials have shown that radiation therapy following conservative surgery lowers the relative risk of progression to invasive disease by 60%. Therefore, followin...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.3.433

    authors: Smith BD,Smith GL,Buchholz TA

    更新日期:2008-03-01 00:00:00

  • Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy.

    abstract::Renal neoplasms exhibit a wide spectrum of molecular characteristics that are closely associated with their diverse morphologic manifestations and clinical behaviors. A wealth of information has been garnered via methodology ranging from classical cytogenetics to FISH and gene expression profiling; however, the exact ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.72

    authors: Cheng L,Williamson SR,Zhang S,Maclennan GT,Montironi R,Lopez-Beltran A

    更新日期:2010-06-01 00:00:00

  • Breast cancer chemoprevention.

    abstract::According to the National Cancer Institute Surveillance Epidemiology and End Results Cancer Statistics Review, the incidence of invasive breast cancer in the USA is 124 women per 100,000 population. Women at increased risk for breast cancer have three major options to reduce their risk, specifically screening, chemopr...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.11.206

    authors: Gabriel EM,Jatoi I

    更新日期:2012-02-01 00:00:00

  • Docetaxel in the treatment of advanced non-small-cell lung cancer.

    abstract::Systemic chemotherapy provides improvement in both survival and quality of life for patients with advanced non-small-cell lung cancer (NSCLC). Docetaxel is the only agent currently approved for both first- and second-line treatment of advanced NSCLC. Multiple randomized clinical trials have established the efficacy of...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.8.1207

    authors: Saloustros E,Georgoulias V

    更新日期:2008-08-01 00:00:00

  • Management of muscle-invasive bladder cancer in the elderly.

    abstract::Bladder cancer is rare in patients below the age of 50 years, and most patients are in their 60s and 70s. Radical cystectomy is the preferred approach for patients with localized disease in most European countries and the USA, and evidence is growing in favor of neoadjuvant, platinum-based chemotherapy for patients at...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.4.6.1017

    authors: Basso U,Bassi P,Sava T,Monfardini S

    更新日期:2004-12-01 00:00:00

  • Kaposi sarcoma as a model of oncogenesis and cancer treatment.

    abstract::Kaposi sarcoma is the most common cancer among HIV-infected individuals and one of the most common cancers in sub-Saharan Africa. Kaposi sarcoma lesions are highly vascularized, and comprised of spindle-shaped tumor cells. Kaposi sarcoma herpesvirus is etiologically linked to Kaposi sarcoma development and encodes gen...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.2.211

    authors: Hansen A,Boshoff C,Lagos D

    更新日期:2007-02-01 00:00:00

  • Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications.

    abstract::Advanced gastric cancer (GC) is a dreadful disease with a poor prognosis and the majority of patients die within 1 year of diagnosis. In the past decade, important signaling pathways promoting tumor proliferation and aggressiveness have been evaluated; the hepatocyte growth factor/mesenchymal epithelial transition (ME...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.974564

    authors: Abdel-Rahman O

    更新日期:2015-02-01 00:00:00

  • ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?

    abstract::Crizotinib (XALKORI™, Pfizer) is a tyrosine kinase inhibitor targeting ALK, MET and ROS1, currently approved for the treatment of adults with ALK-rearranged non-small-cell lung cancer. Optimizing the management of frequent crizotinib-related adverse events is crucial to ensure its continuous administration and reprodu...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.986103

    authors: Girard N,Audigier-Valette C,Cortot AB,Mennecier B,Debieuvre D,Planchard D,Zalcman G,Moro-Sibilot D,Cadranel J,Barlési F

    更新日期:2015-02-01 00:00:00

  • Improving the accuracy in prognosis for Burkitt lymphoma patients.

    abstract::A recent population-based study on 2000 adult patients with Burkitt lymphoma presented a novel score that takes into account age, race and clinical stage to prognosticate survival. The outcome of patients with Burkitt lymphoma has improved in the last decade, likely due to intensive chemotherapy regimens and anti-CD20...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/14737140.2014.866042

    authors: Castillo JJ,Nadeem O

    更新日期:2014-02-01 00:00:00

  • Biomarkers for prostate cancer detection.

    abstract::Since its approval by the US FDA in 1986, prostate-specific antigen (PSA) has been employed to monitor men with a diagnosis of prostate cancer. In 1994, PSA was approved for use in prostate cancer screening and has been employed worldwide. However, due to the limited specificity of PSA for the disease, novel biomarker...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.168

    authors: Reed AB,Parekh DJ

    更新日期:2010-01-01 00:00:00

  • What therapies are on the horizon for HER2 positive breast cancer?

    abstract::Introduction: Despite dramatic improvements in survival achieved with currently available anti-HER2 agents, HER2-positive metastatic breast cancer remains an almost invariably deadly disease, with primary or acquired resistance to HER2-directed agents developing during treatment. Many efforts are focused on identifyin...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2019.1660164

    authors: Viale G,Morganti S,Ferraro E,Zagami P,Marra A,Curigliano G

    更新日期:2019-09-01 00:00:00

  • Evolving classification of renal cell neoplasia.

    abstract::The development of consensus classifications for renal epithelial neoplasia in 1996 and 1997 led to the recognition of renal adenoma, renal oncocytoma and metanephric adenoma/adenofibroma as benign tumors and conventional (clear cell) renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and collecting duct carci...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.1.4.576

    authors: Delahunt B,Velickovic M,Grebe SK

    更新日期:2001-12-01 00:00:00

  • Genetic polymorphisms and endometrial cancer risk.

    abstract::For most sporadic cancers, genetic susceptibility results from the additive effect of multiple genetic variants, each of which contributes a modest risk individually. The study of genetic single nucleotide polymorphisms (SNPs) may help explain the differences in individual cancer susceptibility and may assist in ident...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.7.1159

    authors: Meyer LA,Westin SN,Lu KH,Milam MR

    更新日期:2008-07-01 00:00:00

  • Surgical management of pediatric brain tumors.

    abstract::Brain tumors are the most common cause of cancer-related death and the second most common form of cancer in pediatric patients. Many of these tumors are treated primarily with surgery, either alone or in combination with radiation or chemotherapy. Recent advances have lead to greater survival and decreased morbidities...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.12s.S61

    authors: Heuer GG,Jackson EM,Magge SN,Storm PB

    更新日期:2007-12-01 00:00:00

  • Can diet prevent nonmelanoma skin cancer progression?

    abstract::Nonmelanoma skin cancer is the most prevalent malignant disease among light-skinned individuals in the USA, accounting for approximately 1 million new cases annually. Solar ultraviolet radiation is known to be the major cause of skin cancer. The idea that diet, particularly dietary fat, may play a role in modulating c...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.5.801

    authors: Black HS

    更新日期:2005-10-01 00:00:00

  • Advances in the management of testicular cancer.

    abstract::Although testicular cancer is currently a rare disease, the incidence is rising. The most important risk factor remains cryptorchism and there is a variable association with testicular microlithiasis. Serum tumor markers remain important for diagnosis, and they have prognostic value and can be used to monitor therapy ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.4.4.669

    authors: Balk C,Witjes JA

    更新日期:2004-08-01 00:00:00

  • Minimally invasive cystectomy approaches in the treatment of bladder cancer.

    abstract::Bladder cancer is the most frequently occurring tumor of the urinary system, with over 10,000 new diagnoses each year in the UK. Approximately 70% of these are non-muscle-invasive and limited to the mucosa (Ta) or submucosa (T1). These tumors are generally managed with transurethral resection followed by adjuvant intr...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.52

    authors: Cheung G,Dasgupta P,Guru KA,Billia M,Khan MS

    更新日期:2012-06-01 00:00:00

  • Expression profiling for bladder cancer: strategies to uncover prognostic factors.

    abstract::Despite being a common cancer worldwide, management of transitional cell carcinoma of the bladder currently relies primarily on clinical staging and histopathologic parameters. Assaying alterations in molecular pathways can contribute valuable information that can accurately predict outcome and chemotherapeutic respon...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.131

    authors: Bartsch G,Mitra AP,Cote RJ

    更新日期:2010-12-01 00:00:00

  • Adrenocortical carcinoma: role of laparoscopic surgery in treatment.

    abstract::Adrenocortical carcinoma is a rare disorder with a prevalence of one case per 1.7 million people and a generally poor prognosis. It accounts for 0.02% of all cancer cases and 0.2% of cancer deaths. Within the past three decades, accurate diagnosis, precise radiologic localization, satisfactory preoperative medical man...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.9.1295

    authors: Haleblian GE,Wilson C,Haddad D,Albala DM

    更新日期:2007-09-01 00:00:00